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Background: Hearts treated with L-arginine polymers have demonstrated upregu-
lated production of nitric oxide. The current study examined whether these polymers
improved coronary flow and reduced myocardial oxidative stress after rat heart
transplantation.
Methods: PVG donor hearts were incubated ex vivo with either 100 mol/L
L-arginine polymers 9 amino acids in length (R9) (n  7) or phosphate-buffered
saline (n  7) for 30 minutes after arrest and then transplanted heterotopically into
the abdomen of ACI recipient rats. Coronary flows were assessed using fluorescent
microspheres both at baseline (30 minutes after reperfusion) and at 6 hours and
compared using the paired Student t test. Evidence of oxidative stress was assessed
in a separate cohort of similarly treated animals by enzyme-linked imunosorbent
assay for rat tumor necrosis factor- at 6 hours.
Results: Histochemistry with biotinylated L-arginine polymers demonstrated uptake
of R9 into the vascular walls of treated allografts. Although all hearts experienced
deterioration in coronary flow between baseline and 6 hours, the R9-treated group
had a smaller reduction (29.9%, P .10) than the phosphate-buffered saline control
group (58.0%, P  .003). Tumor necrosis factor- levels were also significantly
reduced in the R9 treatment group compared with the phosphate-buffered saline
category (160  30 versus 205  38, P  .007).
Conclusion: Rat cardiac allografts treated with R9 at the time of procurement
exhibited less deterioration in coronary flow and a reduction in myocardial oxidative
stress than the phosphate-buffered saline control group in the perioperative period.
The use of arginine polymers may thus provide important myocardial protection
against ischemia-reperfusion injury in both transplant and routine cardiac surgery
cases.
Reperfusion of previously ischemic cardiac tissue leads to the gen-eration of oxygen free radicals such as superoxide anions andhydroxyl groups, which in turn cause lipid peroxidation and cellu-lar death.1 These cytotoxic reactive oxygen species initiate aninflammatory response that extends myocardial injury and impairsoverall cardiac function beyond that caused by ischemia alone.2
Nitric oxide (NO) has long been recognized as a potential cardioprotective agent.
In addition to its vasodilatory properties, it is a known free radical scavenger3 as
well as inhibitor of neutrophilic adherence to the vascular endothelium.4,5 NO’s
ability to both attenuate neutrophil chemotaxis as well as scavenge the destructive
by-products of its inflammatory mediators makes it an attractive therapeutic mo-
dality for cardiovascular procedures.
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NO is formed enzymatically by the action of NO syn-
thase on its substrate, L-arginine.6 Various strategies have
been utilized to administer this molecule in experimental
models including providing specific NO donors,7 gene
transfer of inducible NO synthase,8 and exogogenous L-
arginine.9 Recently, it was discovered that polymers of
L-arginine of 6 amino acids (R6) in length or greater were
highly effective in gaining intracellular access. These poly-
mers thus represent a novel method of L-arginine delivery to
biologic systems. Polymers of less than 6 amino acids were
found to be ineffective in crossing cellular membranes.10
Previous experiments in this laboratory indeed found that
treatment of cardiac allografts with L-arginine polymers of 9
amino acids in length (R9) resulted in cellular uptake as
well as upregulation of NO production in these tissues.
These findings were not found in those hearts treated with
shorter L-arginine polymers of 5 amino acids in length.11
The objective of the current study was thus to determine
whether similar treatment of donor hearts with R9 would
increase coronary vasodilatation as assessed by regional
blood flow measures as well as decrease parameters of
reperfusion injury as measured by tumor necrosis factor
(TNF)- levels during the perioperative period. Myocardial
cells have been shown to synthesize and release TNF-
during ischemia-reperfusion injury.12,13
Methods
Peptide Synthesis
L-Arginine polymers were synthesized on an Applied Biosystems
433 peptide synthesizer using previously described solid phase
techniques and commercially available reagents (Applied Biosys-
tems, Foster City, Calif)14 and provided as a gift by Cellgate
Incorporated (Sunnyvale, Calif). The following sequences were
used: R9: NH2-RRRRRRRRR-CONH2 (R  L-arginine) and
phosphate-buffered saline (PBS). Biotinylated polymers were used
in studies assessing translocation of the agent to the vascular walls
of treated hearts.
Animals
Adult pathogen-free male ACI (RT1a) and PVG (RT1c) rats
weighing approximately 250 g were purchased from Harlan
Sprague Dawley (Indianapolis, Ind) and housed at the animal care
facilities at Stanford University Medical Center (Stanford, Calif).
They were provided rat chow and water ad libitum and kept under
standard temperature, humidity, and timed lighting conditions.
Animals were treated in a humane manner in compliance with the
“Guide for the Care and Use of Laboratory Animals” (National
Institutes of Health publication no. 86-23, revised 1985).
Heterotopic Heart Transplantation
Intraabdominal heterotopic cardiac grafting was performed using a
modification of the Ono and Lindsey technique.15 Animals were
anesthetized by inhalation of 1% to 2% methoxyfluorane followed
by intraperitoneal injection of pentobarbital (40 mg/kg). Heart and
respiratory rates were closely monitored. After arrest of the PVG
donor hearts with Stanford Cardioplegia (sodium bicarbonate, 25
mEq/L; potassium chloride, 30 mEq/L; 5% dextrose; and 1.3%
mannitol), 500 L of randomly assigned PBS (n  7) or 100
mol/L R9 (n  7) were administered proximal to an aortic
crossclamp and then incubated within the hearts for 30 minutes in
a 4°C PBS bath. A midline laparotomy was made in intubated
recipient ACI rats, and the donor heart ascending aorta and pul-
monary artery were anastamosed in an end-to-side fashion to the
recipient’s abdominal aorta and vena cava, respectively. The mid-
line laparotomy incisions were then closed, and the animals un-
derwent left lateral thoracotomy exposing the left atrium.
Regional Myocardial Blood Flow Calculations
Fifteen-micron fluorescent microspheres were used to calculate
myocardial regional blood flow (RBF) as previously described.16
Approximately 500,000 spheres (NuFlow; IMT Technologies, Ltd,
Irvine, Calif) were injected into the left atrium 30 minutes after
unclamping and reperfusion of cardiac allografts while a reference
blood sample was drawn for 60 seconds from the left femoral
artery at a set rate.
The animals were then extubated and monitored closely for
signs of distress for a 6-hour period. After this interval, they were
reintubated and their thoracotomy incisions reopened. Fluorescent
microspheres of a different color were then injected in a similar
fashion as described above, after which the cardiac allografts were
procured and the animals killed. Processing of tissues and counting
of microspheres were performed in a blinded fashion by Interac-
tive Medical Technologies, Ltd (Irvine, Calif). Briefly, tissues
were digested in an alkaline reagent (catalog no. 501-105) over-
night. The samples were then centrifuged at 1500 g after which the
supernatant was collected, mixed with a microsphere counting
reagent (catalog no. 501-107), and sonicated. The effluent was then
passed through a 50-m filter and centrifuged, and the supernatant
aspirated to leave a volume of 200 L. The sample was then
briefly sonicated and analyzed by flow cytometry. RBF was cal-
culated according to the following equation: Qi(mL/min) 
(fli/flref)*R(mL/min), where Qi  flow to each segment of myo-
cardium, fli  fluorescence count of each piece, flref  fluores-
cence count of RBF, and R(mL/min)  reference blood with-
drawal rate.
Measurement of TNF- Levels
Additional allografts were treated with 100 mol/L R9 (n 11) or
PBS (n  10) and transplanted heterotopically as described above
to provide tissues samples for TNF- assays. As in the RBF
studies, procurement was performed 6 hours after reperfusion of
the allografts. Fresh tissue samples were homogenized in normal
saline and centrifuged at 4°C for 20 minutes at 10,000 g. The
supernatant was then collected and stored at20°C. TNF- levels
in these supernatant samples were measured by enzyme-linked
immunoassay technique using a commercially available detection
kit (Biosource International, Camarillo, Calif) and standardized to
total protein concentrations determined utilizing a modification of
the Lowry method (Sigma Diagnostics, St Louis, Mo).
Confirmation of Translocation
To demonstrate the ability of R9 penetration of vascular cells,
PVG hearts were isolated as above and incubated for 30 minutes
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with either PBS (n  1) or 100 mol/L (n  1) biotinylated R9.
The hearts were then flushed with PBS solution before harvesting,
freezing in optimal cutting temperature (OCT) compound (Tissue-
Tek, Torrance, Calif) and cutting into 5-m sections. Slides were
fixed in acetone for 10 minutes at 20°C, washed in PBS for 3
separate 5-minute intervals, and incubated for 30 minutes with
peroxidase suppressor (Pierce, Rockford, Ill) to block endogenous
activity. The slides were then washed in PBS as above and incu-
bated with 5 g/mL of horseradish peroxidase-conjugated strepta-
vidin (Pierce) for 30 minutes. They were then washed and incu-
bated for 60 seconds with the horseradish peroxidase substrate,
3,3'-diaminobenzidine (Sigma Diagnostics). Reactions were termi-
nated by rinsing slides in distilled water before methyl green
counterstaining and dehydration in ethanol. Slides were photo-
graphed under 400 magnification.
Statistical Analysis
All intra-animal and interanimal comparisons were made with the
paired and unpaired Student t test, respectively. P values  .05
were considered significant.
Results
L-Arginine Polymer Uptake
Representative photomicrographs at 400 of hearts treated
for 30 minutes with either PBS or biotinylated R9 demon-
strated uptake of the latter within the coronary artery vas-
culature. The PBS-treated hearts showed the methyl green
counterstaining of nuclei within the cells of the tunica
intima and media layers, whereas the R9-treated hearts
demonstrated brown staining indicating the presence of the
biotinylated polymers (Figure 1).
Regional Myocardial Blood Flow
The cardiac allografts demonstrated deterioration in coro-
nary flows as measured by fluorescent microspheres be-
tween the baseline and 6-hour time points. In those hearts
pretreated with R9 polymers, however, the deterioration
was only 29.9% and was not found to be statistically sig-
nificant (P  .10). PBS-treated hearts, on the other hand,
showed a statistically significant 58.0% decline in RBF
between the baseline and 6-hour time points (P  .003).
Mean RBFs for both PBS and R9 groups are shown in
Figure 2.
Measurement of TNF- Levels
TNF- levels as measured by enzyme-linked immunosor-
bent assay were significantly lower in the R9-pretreated
cardiac allografts at the 6-hour time point (160  30 versus
205  38 pg/mL for the R9 and PBS groups, respectively;
P  .007) (Figure 3).
Discussion
Our initial studies utilizing polyarginine therapy in a cardiac
transplant model found an 89% transfection efficiency of
vascular endothelial cells associated with a 30% upregula-
tion in the production of NO.11 The observation that poly-
mers of L-arginine gain intracellular access was first theo-
rized studying the transactivator protein of the human
immunodeficiency virus (tat), which is rich in its concen-
tration of this amino acid,17,18 and confirmed with the work
Figure 1. Representative cross sections at 400 of rat hearts treated ex vivo with either PBS or 100 mol/L
biotinylated R9 for 30 minutes. Areas of R9 uptake are indicated by nuclei darkened by 3,3'-diaminobenzidine
staining of streptavidin-biotin complexes. Note in the PBS-treated group, only the methyl green counterstaining of
nuclei are visible within the vascular wall.
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of Uemura and colleagues,19 who described the uptake of
these polymers in vascular ring segments.
In our original study, chronic rejection as manifested by
graft coronary artery disease (GCAD) was found to be
significantly reduced in L-arginine polymer-treated allo-
grafts at both 60 and 90 days posttransplantation. Although
NO is thought to limit the development of GCAD by inhib-
iting vascular smooth muscle cell proliferation within the
neointimal layer,20 it was conjectured that there may have
also been a contribution from its protective effects on graft
reperfusion injury. GCAD, while primarily immunologi-
cally driven, is known to be exacerbated by early ischemic
injury.21 The current study was thus performed to examine
the ability of L-arginine polymer therapy to inhibit cardiac
injury associated with graft reperfusion as well as document
any increase in regional blood flow due to NO’s vasodila-
tory properties.
Coronary vasospasm after cardiopulmonary bypass may
be a significant cause of postoperative cardiac dysfunction
and even death.22 In many situations, the resulting systemic
hypotension renders the use of traditional vasodilating
agents infeasible. Although direct intracardiac or intracoro-
nary injections of nitroglycerin or calcium channel-blocking
agents have been effective in reversing coronary artery
spasm,23,24 the difficulty of these routes of delivery makes
these methods suboptimal as well.
L-Arginine polymer treatment of hearts undergoing car-
diac arrest potentially circumvents this problem by provid-
Figure 2. Mean RBFs at baseline and 6 hours for both PBS and R9 treatment groups.
Figure 3. TNF- expression is significantly less at 6 hours postreperfusion in the R9 group compared with the
PBS-treated animals.
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ing a means of continuous delivery of NO to the coronary
bed during the perioperative period. The previous study’s
measurement of 30% elevation in NO levels was performed
at 24 hours of postreperfusion. Although the current study
looked at only the 6-hour time point in terms of RBFs, it is
thus feasible that the beneficial effects of NO on coronary
vasomotor tone would have been present for a longer du-
ration during the perioperative period.
Many investigators have utilized L-arginine monomers to
upregulate NO in their biologic models.25-27 Polymers con-
fer the specific advantage over single amino acids in that
there is delivery of multiple units of L-arginine to act as
substrates for NO synthase. In addition, polyarginine uti-
lizes an independent active transport mechanism distinct
from that used by the single amino acids that leads to an
approximate 100-fold increase in its rate of uptake.28
The beneficial effects of L-arginine have been related to
the upregulation of NO with subsequent inhibition of neu-
trophil adherence29,30 and clearance of its free radical by-
products.31 The data in this current study showed a definite
reduction in myocardial injury as manifested by TNF-
production. Although TNF- is released by injured myo-
cardium, it is not a mere marker for reperfusion injury. It is
a cytokine that further contributes to the process of injury by
autoregulating its own production as well as recruiting other
inflammatory mediators such as interleukin-1.32 Its effects
thus include decreased myocardial contractility, decreased
systemic vascular resistance, and resulting hypotension.13
Thus, although the reduced TNF- levels seen with R9
treatment in this study may be indicative of decreased
reperfusion injury, there may have also been a potential
additional therapeutic benefit associated with the reduction
of this rather deleterious inflammatory mediator.
This study did not look specifically at cardiac function,
although it is logical to consider whether the reduction of
vasospasm coupled with the protective effects against reper-
fusion injury would lead to improved perioperative graft
function. Future studies will thus consider functional pa-
rameters such as dp/dt or the load independent measure of
contractility, the preload recruitable stroke work index, to
evaluate whether R9 therapy elicits any improvements in
these endpoints as well. There were no graft failures during
the 6-hour study period in either the PBS or R9 groups.
Future studies may look at increasing the ischemic times
before reperfusion until such a period when graft function is
compromised. R9 therapy can then be compared against
these controls to access whether there are any improvements
in function or survival. Another possibility is to access RBF,
TNF- production, and overall function at increasing time
intervals from surgery. In this way, benefit can be clearly
documented throughout the immediate postoperative pe-
riod.
In conclusion, treatment of cardiac allografts with L-
arginine polymers before transplantation resulted in a re-
duction of deterioration in coronary perfusion as measured
by RBFs as well as decreased evidence of reperfusion injury
as accessed by TNF- levels. Although the model is one of
transplantation, the findings may be relevant to all cardio-
vascular surgeries where cardiopulmonary bypass implies
an inherent ischemic time followed by reperfusion. Future
studies will assess whether the mitigation of ischemia-
reperfusion injury and the improvement in coronary blood
flows with L-arginine polymer therapy will result in func-
tional improvements during the perioperative period.
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